Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Complication of Transplanted Liver Clear all

Conditions: Liver Transplant
Interventions: treprostinil sodium, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Kidney Disease, Liver Disease, Pancreas Disease
Interventions: RIPC by Inflation of Pneumatic Tourniquet; Procedure
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 5 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications, Liver Transplant Complications, Simultaneous Liver-Kidney Transplantation; Complications
Interventions: Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months; Drug
Lead sponsor: Camille N. Kotton, MD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Dallas, Texas

Conditions: Kidney Failure, Hepatitis C, Kidney Disease, Chronic
Interventions: Glecaprevir and Pibrentasvir; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Postoperative Cognitive Complications, Delirium, Perioperative/Postoperative Complications, Brain Injuries, Anesthesia
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Liver Transplant; Complications, Quality of Life, Child Behavior, Adolescent Behavior
Interventions: PeLTQL delivery via electronic means; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 8 Years to 20 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Oakland, California • Atlanta, Georgia • New York, New York + 2 more

Conditions: Liver Diseases, Alcoholic, Alcohol-Related Disorders, Transplant; Failure, Liver, Transplant; Complication, Rejection, Liver Diseases, Hepatitis, Alcoholic, Alcohol-Induced Disorders
Interventions: liver transplant; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cirrhosis, Liver, Sarcopenia
Interventions: Transjugular Intrahepatic Portosystemic Shunt (TIPS) creation; Procedure
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: End Stage Renal Disease, Chronic Hepatitis c
Interventions: Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 34 Years to 44 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: End Stage Renal Disease, End Stage Liver Disease
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: Not listed
Enrollment: 13,767 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Complication of Transplanted Liver
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Kidney Injury, Liver Disease, Chronic Kidney Disease, End Stage Kidney Disease
Interventions: Renal replacement therapy; Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Liver Dysfunction, Rejection, Transplant, Transplantation, Liver
Interventions: Thymoglobulin, Corticosteroid, Tacrolimus, Mycophenolate Mofetil; Biological · Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more

Conditions: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
Interventions: tabelecleucel; Biological
Lead sponsor: Pierre Fabre Medicament; Industry
Eligibility: Not listed
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 40
States / cities: Duarte, California • La Jolla, California • Loma Linda, California + 28 more

Conditions: Obesity, Cardiovascular Disease, Type 2 Diabetes, Hypertension, Complication of Transplant
Interventions: Sleeve Gastrectomy; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Kidney Disease, Liver Transplantation
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Sinusoidal Obstruction Syndrome, Complications of Bone Marrow Transplant
Interventions: shear wave ultrasound elastography; Diagnostic Test
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: Up to 21 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Renal Failure Chronic, Hepatitis C
Interventions: Zepatier, Zepatier plus Sofosbuvir; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Reperfusion Injury, Liver Injury
Interventions: inhaled nitric oxide, nitrogen gas; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Birmingham, Alabama • Seattle, Washington

Conditions: Cirrhosis, Liver, End Stage Liver DIsease, Acute Kidney Injury, Liver Transplant; Complications
Interventions: Angiotensin II, Norepinephrine; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cervical Cancer, Hpv, Warts
Interventions: Quadrivalent HPV for types 6, 11, 16 and 18; Biological
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 9 Years to 17 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Liver Transplant Disorder, Reperfusion Injury
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Liver Transplant, Hepatitis C, Chronic Kidney Disease, Acute Rejection
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Chordoma, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma
Interventions: amifostine trihydrate, busulfan, filgrastim, melphalan, thiotepa, peripheral blood stem cell transplantation (PBSC); Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 1 Year to 45 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

Remote Ischemic Preconditioning In Abdominal Organ Transplantation

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir

Prospective Observational Multimodal Neuromonitoring During High-Risk Adult Surgery

Starzl Network Patient Reported Outcomes

Cohort/Ethics Study of Patients With Severe Alcoholic Hepatitis Undergoing Early Liver Transplantation

Body Composition Changes After TIPS and Associated Clinical Outcomes

Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access

Transplant Patient Registry of Liver, Kidney and/or Pancreas

Genetic Predisposition-Chronic Nephrotoxicity From CI-Liver Transplant Recipients-Potential Correlation-Urinary Biomarkers

Continuous Renal Replacement Therapy in the Setting of Orthotopic Liver Transplant

Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Gastric Sleeve Pilot Study in Morbidly Obese Undergoing Liver Transplantation

Evaluation of Kidney Disease in Liver Transplant Recipients

Using Ultrasound Elastography to Predict Development of SOS

Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant

Study to Evaluate if Inhaled Nitric Oxide Improves Liver Function After Transplantation

Angiotensin 2 for AKI After OLT

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

Cardiac Strain Using Speckle Tracking Echocardiography During Orthotopic Liver Transplantation

Proteogenomic Monitoring and Assessment of Liver Transplant Recipients

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors